在糖尿病前期,久坐式办公室工作者中改善食后高血糖症,午餐后立即进行中等强度运动:使用体力活动追踪器,饮食管理应用程序和持续的葡萄糖监测进行全面评估
Keiko Koide1, Koichiro Azuma2, Yoshihito Atsumi1
1Diabetes Center, Eiju General Hospital, 2-23-16 Higashi-Ueno, Taito-Ku, Tokyo, 110-8645 Japan.
Diabetology international
|July 3, 2025
概括
在糖尿病前期患者中,午餐后立即炼显著改善了食后高血糖症. 这种干预导致了更好的血糖控制,由曲线下面积 (AUC) 的减少和目标范围 (TITR) 的时间增加表明.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 运动生理学 运动生理学
背景情况:
- 糖尿病前期的特点是葡萄糖调节受损.
- 餐后高血糖是糖尿病前期的一个关键特征.
- 像运动这样的生活方式干预对于管理糖尿病前期至关重要.
研究的目的:
- 调查午餐后立即运动对糖尿病前期患者的食后高血糖的影响.
- 评估运动对关键血糖控制指标的影响.
主要方法:
- 一个主题内的交叉设计,将练习阶段与控制阶段 (没有练习) 进行比较.
- 持续葡萄糖监测 (CGM) 用于测量曲线下的面积 (AUC),葡萄糖变化率 (RCMC) 和目标时间 (TITR).
- 身体活动和能量摄入量也被监测.
主要成果:
- 与对照阶段相比,午餐后的运动显著降低了午餐后AUC,并增加了%TITR.
- 在炼阶段,累计AUC显著较低,累计%TITR显著更高.
- RCMC显示了各种变化,HR储备或能量摄入没有显著差异.
结论:
- 午餐后立即炼可以有效改善糖尿病前期患者的食后高血糖症.
- 累计AUC和%TITR的显著改善支持了这一干预措施的有效性.
- 需要进一步的研究,以了解观察到的葡萄糖概况变化背后的机制.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
271
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
271
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431


